Key facts
- This page summarizes Amy Quinlan's Form 4 filing for Vor Biopharma Inc. (VOR).
- 1 reported transaction and 0 derivative rows are listed below.
- Accepted by SEC: 08 Nov 2024, 16:15.
Amy Quinlan - 06 Nov 2024 Form 4 Insider Report for Vor Biopharma Inc. (VOR)
- Reporting relationship
- Vice President of Finance
- Issuer ticker
- VOR
- Reported as of
- 06 Nov 2024
- Net transaction value
- -$177
- SEC form
- 4
- Accepted by SEC
- 08 Nov 2024, 16:15:16 UTC
- Prior SEC filing
- 05 Nov 2024
- Next SEC filing
- 18 May 2026
- Source filing
- View source filing
- Reporting owner signature
- /s/ Katie Kazem, Attorney-in-Fact
Source evidence
Original filing metadata and source links for verification.
5 source fields
Reporting owner
1 detail
Key filing fact
Amy Quinlan filed Form 4 for Vor Biopharma Inc. (VOR) on 08 Nov 2024.
Change
- Previous filing in this sequence was filed on 05 Nov 2024.
- Current net transaction value: -$177.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
VOR
transaction
Common Stock
Tax liability
- Transaction value
- $177
- Shares
- -206
- Change %
- -0.41%
- Price
- $0.8600
- Shares after
- 50,312
- Date
- 06 Nov 2024
- Ownership
- Direct
- Footnotes
- F1
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Section 16 status
Amy Quinlan is no longer subject to Section 16 filing requirements. Form 4 or Form 5 obligations may still apply in specific circumstances.
Explanation of responses 1 footnote
Footnote F1
Shares were withheld to satisfy the Reporting Person's tax withholding obligations in connection with the settlement of restricted stock units.